GUIding multi-moDal thErapies against MRD by liquid biopsies - GUIDE.MRD

Informations projet

GUIDE.MRD

N° de convention de subvention: 101112066

DOI

10.3030/101112066

Date de signature de la CE 17 Mai 2023

Date de début 1 Mai 2023

Date de fin 30 Avril 2028

Financé au titre de

• Health

Coût total

€ 34 948 425,41

Contribution de l’UE

€ 17 660 955,00

Coordonné par

UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
Germany

CORDIS fournit des liens vers les livrables publics et les publications des projets HORIZON.

Les liens vers les livrables et les publications des projets du 7e PC, ainsi que les liens vers certains types de résultats spécifiques tels que les jeux de données et les logiciels, sont récupérés dynamiquement sur OpenAIRE .

Livrables

Documents, reports (4)

Updated Data Management Plan (DMP)

The DMP will be updated based on the progress of WP2 and WP3 and associated deliverables

Healthcare pathway map

Visualization of existing and the (ideal) pathway according to a common framework

Stakeholder/system map

A map representing connectivity, fragmentation and factors in the system that may influence adoption of new technologies and solutions.

Dissemination and exploitation plan, including IPR protection management, communication activities

An initial dissemination, communication and exploitation plan will be created when the project begins and updated yearly. The plan will be organized according to the specific conditions on Availability, Accessibility and Affordability (‘3A’).

Websites, patent fillings, videos etc. (1)

Development of project website and project visual identity

The GUIDE.MRD website will be accessible on the internet with internal access that is password protected

Publications

Conference proceedings (1)

Creation of the ideal health care pathway for integrating ctDNA testing into clinical practice through multi-stakeholder engagement.

Auteurs: Lidewij Vat, Brian Goodman, Eleonora Barile, Estevan Kiernan, Bianca Cucoş, Ana Martins, Mohan Bolisetty, Cathy Elks, Ryan Demers, Muriel De Vos, Riccardo Bertini, Trixia Camacho, Daniel J. Smit, Lui
Publié dans: Journal of Clinical Oncology, Numéro 43, 2025, ISSN 0732-183X
Éditeur: American Society of Clinical Oncology (ASCO)
DOI: 10.1200/JCO.2025.43.16_SUPPL.E23032

Peer reviewed articles (2)

Outlining the statistical analysis of longitudinal ctDNA assays to determine minimal residual disease in patients with pancreatic ductal adenocarcinoma: the GUIDE.MRD project

Auteurs: Brune De Dreuille, Evangelina López De Maturana, Claus Lindbjerg Andersen, Ed Schuuring, Ellen Heitzer, Lidewij Vat, Mark Rogers, Riccardo Bertini, Estevan Kiernan, Ephrem Chin, J. Carl Barrett, Josh
Publié dans: Pancreatology, Numéro 24, 2024, ISSN 1424-3903
Éditeur: Elsevier BV
DOI: 10.1016/J.PAN.2024.05.293

237TiP GUIDE.MRD: A Consortium guiding multi-modal therapies against minimal residual disease (MRD) by liquid biopsy to assess implementation of circulating tumor DNA (ctDNA) in clinical practice to i

Auteurs: K. Pantel, C. Lindbjerg Andersen, E. Schuuring, N. Malats, E. Heitzer, L. Vat, E. Kiernan, E. Chin, J.C. Barrett, J.R. Kapp, M. Thomas, M. Gerling, M. Reck, M. Löhr, P. Hofman, J.T.J.N. Hiltermann, C
Publié dans: Annals of Oncology, Numéro 34, 2025, ISSN 0923-7534
Éditeur: Elsevier BV
DOI: 10.1016/J.ANNONC.2023.09.2960EXTERNALLINK